Broad Street

Tarsus Announces Pricing of $100.0 Million Public Offering

Retrieved on: 
Friday, March 1, 2024

In addition, Tarsus has granted the underwriters a 30-day option to purchase up to an additional 468,750 shares of its common stock at the public offering price, less underwriting discounts and commissions.

Key Points: 
  • In addition, Tarsus has granted the underwriters a 30-day option to purchase up to an additional 468,750 shares of its common stock at the public offering price, less underwriting discounts and commissions.
  • The gross proceeds from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Tarsus, are expected to be approximately $100.0 million, excluding any exercise of the underwriters’ option to purchase additional shares.
  • The offering is expected to close March 5, 2024, subject to the satisfaction of customary closing conditions.
  • Goldman Sachs & Co. LLC, BofA Securities, Guggenheim Securities, LLC and Oppenheimer & Co. are acting as joint book-running managers for the offering.

Tarsus Announces Proposed $100.0 Million Public Offering

Retrieved on: 
Thursday, February 29, 2024

Tarsus also intends to grant the underwriters a 30-day option to purchase up to an additional $15.0 million of shares of its common stock offered in the proposed offering.

Key Points: 
  • Tarsus also intends to grant the underwriters a 30-day option to purchase up to an additional $15.0 million of shares of its common stock offered in the proposed offering.
  • All securities in the proposed offering are to be sold by Tarsus.
  • The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • Goldman Sachs & Co. LLC, BofA Securities, Guggenheim Securities, LLC and Oppenheimer & Co. are acting as joint book-running managers for the offering.

360 Dental Lounge Grand Opening in Mansfield

Retrieved on: 
Tuesday, March 5, 2024

MANSFIELD, Texas, March 5, 2024 /PRNewswire/ -- On March 16, 2024, a brand-new dental practice named 360 Dental Lounge will open on Broad Street in Mansfield, TX. It is locally owned and operated by a husband-and-wife team, Dr. Rushabh Doshi and Dr. Rini Bavishi, who have more than 30 years of combined expertise and experience. After practicing in Irving and Las Colinas, they are excited to become part of and serve the Mansfield community.

Key Points: 
  • MANSFIELD, Texas, March 5, 2024 /PRNewswire/ -- On March 16, 2024, a brand-new dental practice named 360 Dental Lounge will open on Broad Street in Mansfield, TX.
  • After practicing in Irving and Las Colinas, they are excited to become part of and serve the Mansfield community.
  • Ranging from simple dental checkups and cleanings to complex dental implants and other procedures, they have the expertise necessary to meet each patient's unique needs, including specialty services.
  • In the practice, Dr. Bavishi and Dr. Doshi take advantage of the most cutting-edge technology and services available including the following to improve the dental experience and provide these advanced dental procedures:

AMSC Prices Upsized $60 Million Public Offering of Common Stock

Retrieved on: 
Wednesday, January 31, 2024

AMSC expects the gross proceeds from this offering to be $60,750,000, before deducting the underwriting discount and other estimated offering expenses.

Key Points: 
  • AMSC expects the gross proceeds from this offering to be $60,750,000, before deducting the underwriting discount and other estimated offering expenses.
  • AMSC intends to use the net proceeds from this offering for working capital and general corporate purposes.
  • AMSC has granted the underwriters a 30-day option to purchase up to 810,000 additional shares of its common stock.
  • AMSC expects to close the offering, subject to customary conditions, on or about February 2, 2024.

AMSC Announces Proposed Public Offering of Common Stock

Retrieved on: 
Tuesday, January 30, 2024

AMSC also expects to grant the underwriters a 30-day option to purchase additional shares of common stock offered in the public offering.

Key Points: 
  • AMSC also expects to grant the underwriters a 30-day option to purchase additional shares of common stock offered in the public offering.
  • AMSC intends to use the net proceeds from the proposed offering for working capital and general corporate purposes.
  • A shelf registration statement relating to the shares of common stock to be issued in the proposed offering was filed with the Securities and Exchange Commission (SEC) and is effective.
  • A preliminary prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC.

Perspective Therapeutics Announces Closing of $69.0 Million Public Offering and $20.8 Million Private Placement

Retrieved on: 
Monday, January 22, 2024

All of the shares of common stock and pre-funded warrants sold in the public offering were sold by Perspective.

Key Points: 
  • All of the shares of common stock and pre-funded warrants sold in the public offering were sold by Perspective.
  • Gross proceeds to Perspective in the public offering were approximately $69.0 million, before underwriting discounts and commissions and estimated expenses of the public offering.
  • The aggregate gross proceeds from the public offering and the concurrent private placement were approximately $89.8 million, before underwriting discounts and commissions and other offering expenses payable by Perspective.
  • The securities described above in the public offering were offered by Perspective pursuant to a shelf registration statement on Form S-3 (File No.

Perspective Therapeutics Announces Pricing of $60.0 Million Public Offering And $20.8 Million Private Placement

Retrieved on: 
Thursday, January 18, 2024

The aggregate gross proceeds from this public offering are expected to be approximately $60.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Perspective in connection with the public offering.

Key Points: 
  • The aggregate gross proceeds from this public offering are expected to be approximately $60.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Perspective in connection with the public offering.
  • All of the shares of common stock and pre-funded warrants to be sold in the public offering are being sold by Perspective.
  • Oppenheimer & Co. and B. Riley Securities are acting as joint book-running managers for the public offering.
  • The public offering and the concurrent private placement are expected to close on or about January 22, 2024, subject to the satisfaction of customary closing conditions.

Perspective Therapeutics Announces Proposed Public Offering

Retrieved on: 
Wednesday, January 17, 2024

In addition, Perspective intends to grant the underwriters an option for a period of 30 days to purchase up to an additional 15% of the shares of its common stock sold in the public offering at the public offering price, less underwriting discounts and commissions.

Key Points: 
  • In addition, Perspective intends to grant the underwriters an option for a period of 30 days to purchase up to an additional 15% of the shares of its common stock sold in the public offering at the public offering price, less underwriting discounts and commissions.
  • All of the securities to be sold in the public offering are being offered by Perspective.
  • The proposed public offering and concurrent private placement are subject to market conditions and there can be no assurance as to whether or when the offerings may be completed, or as to the actual size or terms of the public offering or concurrent private placement.
  • The securities in the proposed public offering will be offered by means of a prospectus supplement and accompanying prospectus relating to the public offering that form a part of the registration statement.

Voyager Therapeutics Announces Pricing of Public Offering

Retrieved on: 
Friday, January 5, 2024

The purchase price per pre-funded warrant represents the per share public offering price for the common stock, minus the $0.001 per share exercise price of each pre-funded warrant.

Key Points: 
  • The purchase price per pre-funded warrant represents the per share public offering price for the common stock, minus the $0.001 per share exercise price of each pre-funded warrant.
  • The offering is expected to close on or about January 9, 2024, subject to the satisfaction of customary closing conditions.
  • In addition, the Company has granted the underwriters of the offering a 30-day option to purchase up to an additional 1,666,665 shares of its common stock at the public offering price, less underwriting discounts and commissions.
  • A final prospectus supplement relating to the public offering will be filed with the SEC.

Voyager Therapeutics Announces Proposed Public Offering

Retrieved on: 
Thursday, January 4, 2024

All of the securities in the proposed offering are to be sold by the Company.

Key Points: 
  • All of the securities in the proposed offering are to be sold by the Company.
  • The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.
  • The proposed offering is being made pursuant to a shelf registration statement on Form S-3 (File No.
  • The final terms of the proposed offering will be disclosed in a final prospectus supplement to be filed with the SEC.